FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151252098> ?p ?o ?g. }

• W2151252098 endingPage "1680" @default.
• W2151252098 startingPage "1673" @default.
• W2151252098 abstract "Prophylaxis for venous thromboembolism is recommended for at least 10 days after total knee arthroplasty; oral regimens could enable shorter hospital stays. We aimed to test the efficacy and safety of oral rivaroxaban for the prevention of venous thromboembolism after total knee arthroplasty.In a randomised, double-blind, phase III study, 3148 patients undergoing knee arthroplasty received either oral rivaroxaban 10 mg once daily, beginning 6-8 h after surgery, or subcutaneous enoxaparin 30 mg every 12 h, starting 12-24 h after surgery. Patients had mandatory bilateral venography between days 11 and 15. The primary efficacy outcome was the composite of any deep-vein thrombosis, non-fatal pulmonary embolism, or death from any cause up to day 17 after surgery. Efficacy was assessed as non-inferiority of rivaroxaban compared with enoxaparin in the per-protocol population (absolute non-inferiority limit -4%); if non-inferiority was shown, we assessed whether rivaroxaban had superior efficacy in the modified intention-to-treat population. The primary safety outcome was major bleeding. This trial is registered with ClinicalTrials.gov, number NCT00362232.The primary efficacy outcome occurred in 67 (6.9%) of 965 patients given rivaroxaban and in 97 (10.1%) of 959 given enoxaparin (absolute risk reduction 3.19%, 95% CI 0.71-5.67; p=0.0118). Ten (0.7%) of 1526 patients given rivaroxaban and four (0.3%) of 1508 given enoxaparin had major bleeding (p=0.1096).Oral rivaroxaban 10 mg once daily for 10-14 days was significantly superior to subcutaneous enoxaparin 30 mg given every 12 h for the prevention of venous thromboembolism after total knee arthroplasty.Bayer Schering Pharma AG, Johnson & Johnson Pharmaceutical Research & Development." @default.
• W2151252098 created "2016-06-24" @default.
• W2151252098 creator A5012512308 @default.
• W2151252098 creator A5021356441 @default.
• W2151252098 creator A5048290440 @default.
• W2151252098 creator A5054257885 @default.
• W2151252098 creator A5055052720 @default.
• W2151252098 creator A5060311872 @default.
• W2151252098 creator A5061240133 @default.
• W2151252098 creator A5071835932 @default.
• W2151252098 creator A5077272475 @default.
• W2151252098 creator A5086575517 @default.
• W2151252098 creator A5088333216 @default.
• W2151252098 creator A5088406700 @default.
• W2151252098 creator A5090494524 @default.
• W2151252098 date "2009-05-01" @default.
• W2151252098 modified "2023-10-10" @default.
• W2151252098 title "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial" @default.
• W2151252098 cites W2014491911 @default.
• W2151252098 cites W2016234199 @default.
• W2151252098 cites W2022932023 @default.
• W2151252098 cites W2036506340 @default.
• W2151252098 cites W2054169479 @default.
• W2151252098 cites W2071155706 @default.
• W2151252098 cites W2115613150 @default.
• W2151252098 cites W2123192786 @default.
• W2151252098 cites W2150567120 @default.
• W2151252098 cites W2160263071 @default.
• W2151252098 cites W2161023907 @default.
• W2151252098 cites W2441750859 @default.
• W2151252098 doi "https://doi.org/10.1016/s0140-6736(09)60734-0" @default.
• W2151252098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19411100" @default.
• W2151252098 hasPublicationYear "2009" @default.
• W2151252098 type Work @default.
• W2151252098 sameAs 2151252098 @default.
• W2151252098 citedByCount "884" @default.
• W2151252098 countsByYear W21512520982012 @default.
• W2151252098 countsByYear W21512520982013 @default.
• W2151252098 countsByYear W21512520982014 @default.
• W2151252098 countsByYear W21512520982015 @default.
• W2151252098 countsByYear W21512520982016 @default.
• W2151252098 countsByYear W21512520982017 @default.
• W2151252098 countsByYear W21512520982018 @default.
• W2151252098 countsByYear W21512520982019 @default.
• W2151252098 countsByYear W21512520982020 @default.
• W2151252098 countsByYear W21512520982021 @default.
• W2151252098 countsByYear W21512520982022 @default.
• W2151252098 countsByYear W21512520982023 @default.
• W2151252098 crossrefType "journal-article" @default.
• W2151252098 hasAuthorship W2151252098A5012512308 @default.
• W2151252098 hasAuthorship W2151252098A5021356441 @default.
• W2151252098 hasAuthorship W2151252098A5048290440 @default.
• W2151252098 hasAuthorship W2151252098A5054257885 @default.
• W2151252098 hasAuthorship W2151252098A5055052720 @default.
• W2151252098 hasAuthorship W2151252098A5060311872 @default.
• W2151252098 hasAuthorship W2151252098A5061240133 @default.
• W2151252098 hasAuthorship W2151252098A5071835932 @default.
• W2151252098 hasAuthorship W2151252098A5077272475 @default.
• W2151252098 hasAuthorship W2151252098A5086575517 @default.
• W2151252098 hasAuthorship W2151252098A5088333216 @default.
• W2151252098 hasAuthorship W2151252098A5088406700 @default.
• W2151252098 hasAuthorship W2151252098A5090494524 @default.
• W2151252098 hasConcept C126322002 @default.
• W2151252098 hasConcept C141071460 @default.
• W2151252098 hasConcept C2776265017 @default.
• W2151252098 hasConcept C2776301958 @default.
• W2151252098 hasConcept C2778269268 @default.
• W2151252098 hasConcept C2778336525 @default.
• W2151252098 hasConcept C2778661090 @default.
• W2151252098 hasConcept C2778959117 @default.
• W2151252098 hasConcept C2779161974 @default.
• W2151252098 hasConcept C2780011451 @default.
• W2151252098 hasConcept C2780868729 @default.
• W2151252098 hasConcept C2908647359 @default.
• W2151252098 hasConcept C42219234 @default.
• W2151252098 hasConcept C71924100 @default.
• W2151252098 hasConcept C99454951 @default.
• W2151252098 hasConceptScore W2151252098C126322002 @default.
• W2151252098 hasConceptScore W2151252098C141071460 @default.
• W2151252098 hasConceptScore W2151252098C2776265017 @default.
• W2151252098 hasConceptScore W2151252098C2776301958 @default.
• W2151252098 hasConceptScore W2151252098C2778269268 @default.
• W2151252098 hasConceptScore W2151252098C2778336525 @default.
• W2151252098 hasConceptScore W2151252098C2778661090 @default.
• W2151252098 hasConceptScore W2151252098C2778959117 @default.
• W2151252098 hasConceptScore W2151252098C2779161974 @default.
• W2151252098 hasConceptScore W2151252098C2780011451 @default.
• W2151252098 hasConceptScore W2151252098C2780868729 @default.
• W2151252098 hasConceptScore W2151252098C2908647359 @default.
• W2151252098 hasConceptScore W2151252098C42219234 @default.
• W2151252098 hasConceptScore W2151252098C71924100 @default.
• W2151252098 hasConceptScore W2151252098C99454951 @default.
• W2151252098 hasIssue "9676" @default.
• W2151252098 hasLocation W21512520981 @default.
• W2151252098 hasLocation W21512520982 @default.
• W2151252098 hasOpenAccess W2151252098 @default.
• W2151252098 hasPrimaryLocation W21512520981 @default.
• W2151252098 hasRelatedWork W1976604292 @default.

• next